(MENAFN- PR Newswire)
Unprecedented Body of New Clinical Evidence using the MolecuLight
Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
TORONTO and SALT LAKE CITY, Utah, Nov. 10, 2022 /PRNewswire/ --
., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that its technology will be featured in over 10 clinical presentations and posters at the , titled Technology in Wound Care . The national conference, hosted from November 10 - 12, 2022 in Salt Lake City, Utah, will focus on the utility of new technologies to improve wound care delivery and clinical outcomes. It will include a combination of nine clinical posters, a clinical talk and a hands-on workshop featuring the MolecuLight devices.
'The technological innovation surge in wound care is transforming how we practice. At the Technology in Wound Care conference, we bring together the most novel and impactful technologies to share evidence and clinician insights into how they improve treatment decisions and patient outcomes', says Alisha Oropallo, MD, FACS,
FSVS, FAPWCA, FABWMS, AAWC Conference Co-Chair and
Medical Director of the Comprehensive Wound Healing Center and Hyperbarics at Northwell Health, New York. 'MolecuLight has extensively validated their point-of-care imaging technology for detection of wound regions harboring clinically concerning bacterial loads and for digital wound measurement. They are a market leader and have set the standard of validation evidence for wound imaging technologies. As such, it is appropriate that MolecuLight is featured in so many clinical presentations, demonstrations, and posters, including over 1,800 new wounds' worth of evidence being shown at this meeting. This innovative technology has become a standard of care in my practice, where it serves as an essential tool to inform and enhance our clinical decision-making.'
New evidence from MolecuLight to be presented at AAWC 2022 includes:
validation of the role this technology can play in addressing racial inequities in wound infection assessment, real-world findings from providers across the US on the treatment plan changes and outcome improvements that result from the implementation of MolecuLight, and further validation of the device's digital wound area measurement capability, which is now stickerless.
The specific clinical presentation and posters featuring the MolecuLight i: X and DX from AAWC 2022 are as follows:
Advances in Addressing the Wound and Skin Microbiome Tomas Serena, MD, FACS, FAAWC Friday, Nov 11, 2022, 1:30pm - 2:05pm
Fluorescence imaging prompts more thorough debridement of bacteria & biofilm: Real worlddata from 1000 wound assessments across 36 states Ashley Jacob*, BSN RN; Laura M. Jones*, PhD; Nathan Krehbiel*, BSN RN; Audrey Moyer-Harris*, BSN RN MBA CWS; Alyssa McAtee, PT, DPT; Isabel Baker, BSN RN, WCC, OMS*; Monique Y. Rennie*, PhD poster
Point-of-Care Fluorescence Imaging Reveals Extent of Chronic Inhibitory Bacterial Load in Diabetic Foot Ulcers Tomas E. Serena, MD FACS; David Armstrong, DPM MD PhD, Michael E. Edmonds
Closing the gap on racial disparities in diagnosis of chronic wound infections: the concerning trend involving skin pigmentation and a role for fluorescence imaging Jonathan Johnson, MD MBA CWSP; Alton Johnson Jr., DPM FACPM DABPM CWSP; CharlesAndersen, MD FACS; Martha Kelso, RN HBOT;
Alisha Oropallo, MD FACS; Tomas Serena, MD FACS
Location matters when sampling a wound: The impact of fluorescence imaging on microbiological findings and its role in diagnostic & antibiotic stewardship Thomas Serena, MD FACS; Philip Bowler, Monique Y. Rennie, PhD poster The Role of Fluorescence Bacterial Scanning in the Identification & Treatment of Intertriginous Bacteria in Diabetic Feet Charles Andersen, MD FACS; Katherine McLeod, RN; Rowena Steffan, RN poster
Incorporating clues from imaged wound dressing in high bacterial loads & infection treatmentplanning Charles Andersen, MD FACS; Katherine McLeod, RN; Rowena Steffan, RN poster
Wound Hygiene Face-off: Scrub vs Soak Alisha Oropallo, MD; Amit Rao, MD; Jai Joshi
Accuracy and reproducibility of device-based stickerless digital wound measurement software Danielle Dunham; Monnie Y. Rennie, PhD; Liis Teene; Rose Raizman
Underappreciated bacterial burden in pressure injuries throughout: clinical trial and real-world evidence Charles Andersen, MD FACS; Katherine McLeod, RN; Rowena Steffan, RN; Tomas Serena, MD
In addition to the clinical posters and presentations at , the MolecuLight i: X® and DX ™ imaging devices will be featured in the Integrating Technology Into Wound Care
hands-on workshop on Thursday, November 10, 2022.
They will also be available for demonstration in the MolecuLight booth #2 in the 2nd Level Ballroom at the Hilton Salt Lake City Center, Salt Lake City, UT.
The MolecuLight i: X and DX are the only imaging devices for the real-time detection of elevated bacterial burden in wounds that are FDA cleared and CE and Health Canada approved. With clinical evidence including over , they are used by leading wound care facilities globally. About
a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercial devices, which include the MolecuLight i: X®
and DX ™
fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the and . MolecuLight procedures performed in the United States benefit from an available which includes two CPT®
codes for physician work to perform 'fluorescence imaging for bacterial presence, location, and load' and facility payment for H ospital O utpatient D epartment ( HOPD ) and A mbulatory S urgical C enter ( ASC ) settings through an A mbulatory P ayment C lassification ( APC ) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.
CONTACT: Rob Sandler, Chief Marketing Officer, MolecuLight Inc., T. +1.647.362.4684,
SOURCE MolecuLight Inc.